In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany’s Pricing Revolution: Why The World Should Be Watching

Executive Summary

Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.

Advertisement

Related Content

ACOs Get In Gear, Accelerating Biopharma’s Value Imperative
Germany To Disclose Rx Pricing Discounts, Setting A Potential Benchmark For Europe
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
For Novartis, 2012 Is Set To Be A Bumpy Ride
German HTA Assessment Knocks Back Gilenya In Europe
Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D
Intermune’s Esbriet Flops In Front Of IQWiG
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
German Reimbursement Decisions Will Remain Officially Opaque In New Law
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel